Resultado de búsqueda
Katherine A. High is an American doctor-scientist who is an emeritus professor at the Perelman School of Medicine at the University of Pennsylvania. She was the co-founder, president, and chief scientific officer of Spark Therapeutics and currently serves as President of Therapeutics at AskBio.
27 de oct. de 2016 · Our Faculty. Katherine A. High, M.D. Emeritus Professor of Pediatrics (Hematology) Attending Physician, The Children's Hospital of Philadelphia. Attending Physician, Hospital of the University of Pennsylvania. Attending Physician, Presbyterian Hospital Medical Center.
27 de oct. de 2016 · Dr. High, a world renowned hematologist, studies the molecular basis of blood coagulation and the development of novel therapeutics for the treatment of bleeding disorders. Her pioneering bench-to-bedside studies of gene therapy for hemophilia have led to a focus on clinical translation of genetic therapies for hemophilia and other ...
Es investigadora del Howard Hughes Medical Institute, entidad sin ánimo de lucro dedicada a la investigación médica con sede en Maryland, y directora del Centro para Terapias Celulares y Moleculares del Hospital de Niños de Filadelfia.
15 de mar. de 2017 · Katherine A. High is Emeritus Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania. A renowned hematologist, her research group pioneered safe and effective clinical translation of genetic therapies for inherited disorders.
Membership Type: Member (elected 2021) Biosketch. Katherine High is recognized for her pioneering research and development of gene therapies for genetic disease. She is known for her studies in adeno-associated viral (AAV)-mediated gene therapy for hemophilia, including the development of AAV vectors that brought about long-term improvement in ...
6 de may. de 2021 · President, Therapeutics. AskBio. Dr. Katherine High trained in internal medicine, hematology, and molecular genetics. Her pioneering bench-to-bedside studies of gene therapy for hemophilia led to a series of basic and clinical investigations that characterized the human immune response to AAV gene delivery vectors.
